Expanded View Figures




Figure EV1. Currents of partially plasma membrane directed "WT" CIC-3 and its E224A mutant.

- A When transfected into HeLa cells, wild-type ClC-3 (green) localized to enlarged Lamp-1-positive (red) late endosomes/lysosomes, GFP-ClC-3^{4xLA} (green) co-localizes with Lamp-1 (red) in normal sized vesicular structures, but is also partially redirected to the plasma membrane. DNA stained with DAPI [scale bar at bottom: 20 μm (for all panels); scale bar in inset: 5 μm].
- B Current–voltage relationships of HeLa cells, either non-transfected controls or transiently transfected with GFP-CIC- 3^{4xLA} ("WT") and GFP-CIC- 3^{4xLA} E224A ("E224A"). Cells were examined 48–72 h post-transfection by whole-cell patch-clamp using 1-s voltage pulses and 20-mV increments from -80 to +140 mV. n.t., not transfected. Mean values \pm SEM "WT", n = 8; "E224A", n = 4; n.t., n = 4, *P < 0.05, MW test. Currents of surface-directed GFP-CIC- 3^{4xLA} were strongly outwardly rectifying and similar to CIC-3 currents reported by others (Li *et al*, 2002; Picollo & Pusch, 2005; Matsuda *et al*, 2008; Guzman *et al*, 2013) and as described for a CIC-5/CIC-3 chimera (Rohrbough *et al*, 2018). They resembled currents of CIC-4 and CIC-5 (Steinmeyer *et al*, 1995; Friedrich *et al*, 1999) but were only barely above background. Mutating the "gating glutamate" E224 to alanine abolished rectification, as reported for CIC-3 (Li *et al*, 2002; Matsuda *et al*, 2008; Rohrbough *et al*, 2018), CIC-4, and CIC-5 (Friedrich *et al*, 1999) and CIC-7 (Leisle *et al*, 2011). These low expression levels precluded measurements of H⁺-transport, but recent studies using CIC-5/3 chimeras convincingly demonstrate that CIC-3 is a CI⁻/H⁺-antiporter which can be uncoupled by the E224A ("unc") mutation (Rohrbough *et al*, 2018).
- C Example traces of GFP-CIC-3^{4xLA} ("WT") and GFP-CIC-3^{4xLA} E224A ("E224A").

CIC-4

β-actin





Figure EV2. Effect of CIC-3 on CIC-4 levels and glycosylation in various tissues.

- A Western blots for CIC-3, CIC-4, and CIC-5 of membrane fractions isolated from brain and kidney from mice of the indicated genotypes. Whereas CIC-4 protein levels depend on CIC-3, CIC-3 levels do not depend on CIC-4. β-Actin served as a loading control.
- B Immunoblots for CIC-3 and CIC-4 of membrane fractions isolated from indicated organs of WT and *Clcn3^{-/-}* mice (indicated by +/+ and -/-). β-Actin, loading control. The different sizes of CIC-4-positive bands most likely result from differences in glycosylation between tissues. Disruption of CIC-3 leads to the appearance, or increase in intensity, of the lowest band that represents the immature protein. The ratio between CIC-3 and CIC-4 proteins apparently differs between tissues.
- C Effect of PNGase F on CIC-4 in brain and liver membrane fractions of WT (+/+) and Clcn3^{-/-} (-/-) mice. Removal of N-linked glycans by PNGase F reveals that apparent size differences of CIC-4 between WT and Clcn3^{-/-} tissues are owed to less glycosylation of CIC-4 in the absence of CIC-3.
- D Treatment of brain and liver membranes with EndoH reveals that a large portion of CIC-4 in Clcn3^{-/-} tissue has not left the ER. The arrows are pointing to the fractions of CIC-4 protein that are sensitive to endoglycosidase H treatment, i.e., has not been modified in the Golgi.

100

50

Α



В




Figure EV3. Expression and subcellular localization of ^{Venus}CIC-3 in cultured glial cells.

- A Primary cultured glial cells were labeled for ^{Venus}CIC-3 (green) and GFAP or APC (red, left and right panel, respectively), markers for astrocytes and oligodendrocytes, respectively (scale bar: 10 μm for main panels; scale bar in insets: 5 μm).
- B Primary cultured astrocytes were labeled for ^{Venus}CIC-3 (green) and rab4 (i, red), EEA1 (ii, red), TfR (iii, red), and Lamp-1 (iv, red) (scale bars: 20 μm in i, iii, and iv; 10 μm in ii). The inlays depict magnified views of boxed sections. DNA stained with DAPI.




Figure EV4. Characterization and quantification of CIC-3 in LP2 fraction.

- A, B Characterization of SV-enriched LP2 fraction. (A) Western blots for CIC-3, CIC-4, synaptophysin, and PSD95 (postsynaptic marker) of fractions obtained during synaptic vesicle-enriched fraction (LP2) preparation using differential centrifugation as described (Huttner *et al*, 1983; Takamori *et al*, 2000). (B) Immunoblots for different cellular markers comparing whole lysate (H) and synaptic vesicle-enriched fraction (LP2) (GM130, Golgi marker; PDI, ER marker; rab4, early endosomes and SV; cathepsin D, lysosomal marker; synaptophysin, SV marker).
- C-E Quantification of CIC-3 in LP2 fractions (C) Western blot of lysates from HEK cells transiently overexpressing either mVGLUT1 or hCIC-3, which were both fused at their N terminus to GFP. Probing for the GFP tag allows to directly compare the relative amount of CIC-3 and VGLUT1 in the lysate for its use as calibration standards for anti-CIC-3 and anti-VGLUT1 antibodies in Western blots of tissue standards [as in (D) and (E)]. (n = 3 independent transfections, horizontal lines and error bars represent mean values SEM). The standard contains about 4.33 × more CIC-3 molecules than the standard for VGLUT1. (D) Example immunoblot for VGLUT1 in which the GFP-VGLUT1 standard [same lysate as in (A)] is compared to different amounts of LP2 fraction. Below, example plot in which WB signals are plotted against rising amounts of the LP2 fraction, quantified by protein contents. The standard for VGLUT1 roughly corresponds to 2.5 µg of LP2 fraction (averaged from n = 6 Western blots). (E) Same as shown in (D) but for CIC-3. The standard for CIC-3 roughly corresponds to 140 µg of the LP2 fraction (n = 7). From (A) and (B), we calculated a molecular ratio for CIC-3/VGLUT1 $\approx 2.5/(140^{+4.33}) = 4.12 \times 10^{-3} = 1/243$ in our LP2 fraction. Considering that CIC-3 may form not only hetero- but also homodimers and that SVs are ~ 2 -fold enriched in the SV compared to the LP2 fraction (Huttner *et al*, 1983) and that there are ~ 10 copies of VGLUT1 per vesicle (Takamori *et al*, 2006), our data yield an upper limit of one CIC-3-containing compartments like endosomes, as found in this work, will lower this estimate. The ~ 20 -fold lower value for the CIC-3/VGLUT1 ratio given by (Schenck *et al*, 2009) may have been caused by their calibration of the VGLUT1 antibody (Synaptic Systems) that recognizes an epitope at the C terminus of VGLUT1. It might have been shielded by the GFP, which these authors fused directly to the carboxy terminus of VGLUT1, thereby overestimating the number of VGLUT1 molecules in their preparatio




Figure EV5. Clcn3^{-/-} mice display normal synaptic ultrastructure.

A Quantification of SVs and endosome-like vacuoles (ELVs) of glutamatergic spine synapses from layer 4–5 of secondary visual cortex of P14, P21, and P70 days-old $Clcn3^{+/+}$ and $Clcn3^{-/-}$ animals. Mean \pm SEM is shown. Five animals per genotype, 20–25 boutons/animal.

B Example electron micrographs illustrating normal morphology of the pre- and Clcn3^{-/-} mice (scale bar: 250 nm).
C Histogram indicating the distribution of synaptic vesicles sizes of Clcn3^{+/+} and Clcn3^{-/-} mice. Five animals per genotype, around 150 vesicles/animal.
D Cumulative plot represents the SV size distribution in Clcn3^{+/+} and Clcn3^{-/-} mice. Five animals per genotype, around 150 vesicles/animal.

E Mean area of all vesicles is unchanged between Clcn3^{+/+} and Clcn3^{-/-} mice. Mean ± SEM is shown. Five animals per genotype, around 150 vesicles/animal.